Do you generally switch aspirin to another antiplatelet agent if a patient has a non-embolic ischemic stroke and isn't a candidate for DAPT?

I do tend to switch, mainly to impress the patient that I am trying hard to prevent another stroke, and not because there is clear evidence of one antiplatelet over another. Clopidogrel or ticagrelor would be candidates, or I might add cilostazol to aspirin, as this combination has little bleeding r...

After an acute non-embolic stroke, based on the CHANCE and POINT trials, would give 21 days of dual antiplatelet therapy, after which can continue aspirin.

Would look for atrial fibrillation, as 20% of lacunar strokes can be the result of non-lacunar mechanisms.

With the advent of factor XI, would con...